Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $515000.0.

  • Rocket Pharmaceuticals' Other Non-Current Assets rose 238.57% to $515000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $515000.0, marking a year-over-year increase of 238.57%. This contributed to the annual value of $529000.0 for FY2024, which is 75.05% down from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Other Non-Current Assets of $515000.0 as of Q3 2025, which was up 238.57% from $515000.0 recorded in Q2 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' Other Non-Current Assets peaked at $608000.0 during Q4 2022, and registered a low of $455000.0 during Q1 2021.
  • In the last 5 years, Rocket Pharmaceuticals' Other Non-Current Assets had a median value of $503000.0 in 2024 and averaged $497842.1.
  • In the last 5 years, Rocket Pharmaceuticals' Other Non-Current Assets skyrocketed by 3362.64% in 2022 and then tumbled by 1233.55% in 2023.
  • Quarter analysis of 5 years shows Rocket Pharmaceuticals' Other Non-Current Assets stood at $455000.0 in 2021, then surged by 33.63% to $608000.0 in 2022, then decreased by 12.34% to $533000.0 in 2023, then fell by 0.75% to $529000.0 in 2024, then fell by 2.65% to $515000.0 in 2025.
  • Its Other Non-Current Assets stands at $515000.0 for Q3 2025, versus $515000.0 for Q2 2025 and $514000.0 for Q1 2025.